Arena Pharma (ARNA) Enters $33M Financing Agreement with Deerfield Management
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) has agreed to sell 9,953,250 shares of its common stock, at a price of $1.65775 per share, and approximately 9,953 shares of its Series D Convertible Preferred Stock, at a price of $1,657.75 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization. The preferred stock is convertible into an aggregate of 9,953,250 shares of Arena common stock. Arena expects to receive gross proceeds of approximately $33 million. The closing of the offering is expected to take place on or about January 13, 2012.
Arena will use $5 million of the proceeds from this offering to prepay a portion of the loan principal that otherwise would have been required to be repaid in June 2013 under the existing Facility Agreement between Arena and Deerfield.
Arena will use $5 million of the proceeds from this offering to prepay a portion of the loan principal that otherwise would have been required to be repaid in June 2013 under the existing Facility Agreement between Arena and Deerfield.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
- MAIA Biotechnology (MAIA) files $150M mixed shelf
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
Deerfield ManagementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share